3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
3
Terminated
1
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 2a
1
Lung Neoplasms
1
Lung Diseases
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Colonic Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
263
Radiotherapy
166
Cetuximab
159
Docetaxel
105
Fluorouracil
104
pembrolizumab
94
Radiotherapy, Intensity-Modulated
83
Carboplatin
80
Paclitaxel
73
Nivolumab
59
Erlotinib Hydrochloride
35
Surveys and Questionnaires
32
Gemcitabine
32
durvalumab
30
Radiation
29
Drug Therapy
25
Immunohistochemistry
21
Gefitinib
21
Capecitabine
21
tremelimumab
18
Bevacizumab
18
Surgical Procedures, Operative
17
Sorafenib
17
Magnetic Resonance Spectroscopy
17
Ipilimumab
17
Pemetrexed
16
lenvatinib
15
atezolizumab
15
Radiosurgery
15
Gene Expression Profiling
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
pralsetinib
×
Head & Neck
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA